Company intelligence / Profile preview

iRegene Therapeutics

Ownership: Private
Development stage: Other

Overview

iRegene Therapeutics has developed a unique "AI + chemical induction" platform to generate universal allogeneic cell therapies from induced pluripotent stem cells. Its lead product NouvNeu001 has shown significant improvement in motor scores with good safety profile in mid-to-late stage Parkinson’s disease patients during ongoing multicenter clinical studies. The company also received FDA Orphan Drug Designation for its retinal disease program NouvSight001. Clinical trials are underway or planned across multiple neurodegenerative and degenerative conditions.

Therapeutic areas: OphthalmologyGastroenterologyCardiovascularNeurology
Modalities: Cell therapy (chemically defined/allogeneic)Induced pluripotent stem cells (iPSC)Exosomes
Industry: Biotech

Drug pipeline

6 assets

NOUVNEU001

5 more assets in the full pipeline.

Beyond the preview

Go deeper on iRegene Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iRegene Therapeutics.